HIV-focused biopharma
Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company whose revenue is led by HIV medicines, with additional sales from liver disease, oncology and cell therapy products. It distributes most U.S. products through large pharmaceutical wholesalers and spends on outsourced manufacturing, collaborative R&D and product royalties.
GILD Updated Sep 11, 2026 5 AI consumers· 3 recurring
Per the valuechain.wiki graph, Gilead Sciences, Inc. is directly linked to 6 companies (3 supply, 3 revenue relationships) and reaches 11 companies within two hops; the links are backed by 7 dated sources, 5 of them primary filings (as of 2026-09-11).
Financials & Segments
- Total revenue · $29.443 billion of total revenue in FY2025
- Segments · HIV · Liver Disease · Oncology · Veklury · Other Products · Royalty, Contract and Other
Revenue from
- Cardinal Health High confidence· Revenue share 29% · FY2025 · Cardinal Health and specialty distributor affiliates' share of Gilead total gross product sales
Cardinal Health and its specialty distributor affiliates are major U.S. wholesale customers of Gilead. They represented 29% of Gilead's total gross product sales in FY2025. - McKesson Corporation High confidence· Revenue share 24% · FY2025 · McKesson and specialty distributor affiliates' share of Gilead total gross product sales
McKesson and its specialty distributor affiliates are major U.S. wholesale customers of Gilead. They represented 24% of Gilead's total gross product sales in FY2025. - Cencora High confidence· Revenue share 21% · FY2025 · Cencora and specialty distributor affiliates' share of Gilead total gross product sales
Cencora and its specialty distributor affiliates are major U.S. wholesale customers of Gilead. They represented 21% of Gilead's total gross product sales in FY2025.
Pays to
- Yuhan Corporation High confidence· Amount ₩210.2B · HIV 원료 공급계약
Gilead sources HIV and hepatitis C (HCV) active pharmaceutical ingredients from Yuhan Chemical, a Yuhan subsidiary. HIV API contract KRW 210.2bn (US$139.8m, 9.61% of Yuhan's 2025 consolidated revenue, 2026-05-19); HCV API contract KRW 85.0bn (US$61.3m, 2025-08-26). - Shionogi & High confidence· Amount $112M · FY2025 · Royalties due to Shionogi related to Genvoya and Stribild
Shionogi assumed Japan Tobacco's rights and obligations under the Gilead agreements in 2025. Gilead pays product-sales-based royalties tied to Genvoya and Stribild, recording $112 million of expense in FY2025. - Samsung Biologics Medium confidence· Contract value ₩300.5B · 계약 누계 공개액 · Samsung Biologics contract-manufacturing value for Gilead, formerly Immunomedics
A Hana Securities review of Samsung Biologics' supply contracts identifies Gilead as a contract-manufacturing customer. The table records a KRW 300.5 billion contract and notes the 2021 counterparty change and volume increase.Confirms KO Hana Securities Published Jan 30, 2023: Samsung Biologics: 4Q22 Review, a Stabilization Year Before the Next Leap
Investments
- Arcus Biosciences, Inc. High confidence· Amount $320M · Q1 2024 · Total equity investment for 15.2 million additional Arcus Biosciences common shares
Gilead purchased an additional 15.2 million shares of Arcus Biosciences common stock in 2024 for $21 per share and $320 million in total. The transaction raised its ownership stake to about 33%.Confirms EN Arcus Biosciences Investor Relations Published Jan 29, 2024: Gilead and Arcus Announce Amended Collaboration and Equity Investment
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| CVS Health | lead2 | +54.9 | -7.6 | -12.5 | -40.8 | +84.3 | +24.7 |
| Walmart Inc | lead2 | +2 | -0.5 | +12.9 | +74 | +24.5 | -3.2 |
| Cardinal Health, Inc. | lead1 | -0.4 | +54.1 | +34.1 | +19 | +76.3 | +21.1 |
| McKesson Corporation | lead1 | +44.2 | +51.8 | +24.1 | +23.7 | +44.5 | +11 |
| Cencora, Inc. | lead1 | +44.1 | +26.3 | +25.3 | +10.4 | +51.5 | -1.4 |
| Gilead Sciences, Inc. | node | +30 | +23.6 | -2 | +18.7 | +36.6 | +24.5 |
| Shionogi & | benef1 | +15 | -2.2 | +17.8 | -1 | +42.4 | -7.3 |
| Samsung Biologics | benef1 | -6.8 | +8.6 | +5.8 | +28.7 | +5 | -17.1 |
| Yuhan Corporation | benef1 | -9 | -2.3 | +19.7 | +119.9 | -16.7 | -24.2 |
| Samsung E&A | benef2 | +74.5 | +20 | -13.7 | -15.9 | +76.7 | +48.9 |
| Danaher Corporation | benef2 | +48.6 | -19 | -1.2 | -0.3 | +0.4 | -8.9 |
| Oscotec | benef2 | -17 | -38.1 | -0.3 | +39.8 | +108.2 | -34.2 |
YTD as of 2026-09-04 · source: Yahoo Finance
Gilead Sciences, Inc. operates across HIV-focused biopharma. It is +24.5% in 2026. The stock (+24.5%) and its supply side (avg -20.6%) are moving in step. Among connected nodes the furthest ahead is Samsung Biologics (-17.1%) and the furthest behind is Yuhan Corporation (-24.2%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. products through large pharmaceutical wholesalers and spends on outsourced manufacturing, collaborative R&D and product royalties.
Analysis generated from returns as of 2026-09-04